儿童急性淋巴细胞白血病中聚乙二醇门冬酰胺酶提前终止后的复发风险
本研究纳入1401例1至17岁、2008年7月至2016年2月诊断、按NOPHO ALL2008方案治疗的儿童ALL患者,评估因毒性或沉默性失活导致门冬酰胺酶暴露不足后的复发风险。
要点
- 强调治疗药物监测和适时调整门冬酰胺酶治疗的重要性。
核心结论
- 因临床毒性截断门冬酰胺酶治疗未显著增加复发风险,但包含沉默性失活的截断与失活亚组复发风险显著升高。
- 结果强调在可行时进行治疗药物监测并适当调整门冬酰胺酶治疗的重要性。
研究设计与样本
- 纳入1401例1至17岁、2008年7月至2016年2月诊断的儿童ALL患者,均按NOPHO ALL2008方案治疗(包括延长门冬酰胺酶暴露:1000 IU/m2肌内注射,第5-33周)。
- 患者从末次门冬酰胺酶治疗或检测到沉默性失活时延迟进入随访,随访至复发、死亡、第二恶性肿瘤或随访结束(中位5.71年,四分位距4.02-7.64)。
主要发现
- 在仅纳入有酶活性信息的患者(n=1115)的亚研究中,截断或沉默性失活者(n=301;157例超敏反应、53例胰腺炎、14例血栓、31例其他、46例沉默性失活)7年累积复发率为11.1%(95%CI 6.9-15.4),其余814例为6.7%(95%CI 4.7-8.6)。
临床怎么用
- 对接受聚乙二醇门冬酰胺酶治疗的儿童ALL患者,应考虑治疗药物监测以及时发现沉默性失活。
- 在可行时,对因毒性截断治疗的患者适当调整门冬酰胺酶治疗,以降低复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Truncation of asparaginase treatment due to asparaginase-related toxicities or silent inactivation (SI) is common and may increase relapse risk in acute lymphoblastic leukemia (ALL). We investigated relapse risk following suboptimal asparaginase exposure among 1401 children aged 1 to 17 years, diagnosed with ALL between July 2008 and February 2016, treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol (including extended asparaginase exposure [1000 IU/m2 intramuscularly weeks 5-33]). Patients were included with delayed entry at their last administered asparaginase treatment, or detection of SI, and followed until relapse, death, secondary malignancy, or end of follow-up (median, 5.71 years; interquartile range, 4.02-7.64). In a multiple Cox model comparing patients with (n = 358) and without (n = 1043) truncated asparaginase treatment due to clinical toxicity, the adjusted relapse-specific hazard ratio (HR; aHR) was 1.33 (95% confidence interval [CI], 0.86-2.06; P = .20). In a substudy including only patients with information on enzyme activity (n = 1115), the 7-year cumulative incidence of relapse for the 301 patients with truncation of asparaginase treatment or SI (157 hypersensitivity, 53 pancreatitis, 14 thrombosis, 31 other, 46 SI) was 11.1% (95% CI, 6.9-15.4) vs 6.7% (95% CI, 4.7-8.6) for the 814 remaining patients. The relapse-specific aHR was 1.69 (95% CI, 1.05-2.74, P=.03). The unadjusted bone marrow relapse-specific HR was 1.83 (95% CI, 1.07-3.14, P=.03) and 1.86 (95% CI, 0.90- 3.87, P=.095) for any central nervous system relapse. These results emphasize the importance of therapeutic drug monitoring and appropriate adjustment of asparaginase therapy when feasible. This trial was registered at www.clinicaltrials.gov as #NCT03987542.
引用
- Gottschalk Højfeldt S, Grell K, Abrahamsson J, et al. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood. 2021. PMID: 33150360. doi:10.1182/blood.2020006583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。